Literature DB >> 30235426

Atrio-ventricular Block Following Neostigmine-Glycopyrrolate Reversal in Non-heart Transplant Patients: Case Report.

Njinkeng J Nkemngu1, Joel N Tochie2.   

Abstract

Neostigmine is the anticholinesterase drug most commonly used to reverse blockade or speed up recovery from neuromuscular blockade from nondepolarizing neuromuscular blocking drugs. Because of its cardiac muscarinic effects, prior or simultaneous administration of glycopyrrolate or atropine is usually recommended. There have been a few case reports of bradycardia, atrio-ventricular (AV) block, and cardiac arrest following neostigmine/glycopyrrolate administration to reverse neuromuscular block affecting several patients. In this report, we describe a case of 21-year-old with a history of seizure disorder and developmental delay that presented for dental surgery under general anesthesia and developed type I AV block following the simultaneous administration of neostigmine and glycopyrrolate to reverse a nondepolarizing neuromuscular block with rocuronium at the end of his surgery. We suggest that the chronic use of antiepileptic drugs in this patient in combination with neostigmine and glycopyrrolate lead to AV block in this patient. We also review similar cases reported in the literature and suggest an explanation for this observed phenomenon.

Entities:  

Keywords:  AV-block; Glycopyrrolate; Neostigmine; Neuromuscular block reversal

Mesh:

Substances:

Year:  2018        PMID: 30235426      PMCID: PMC6148699          DOI: 10.2344/anpr-65-03-10

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  17 in total

1.  "Crime scene investigation" at an anesthetic cocktail party with atrioventricular dissociation.

Authors:  Christoph J Schlimp; Franz J Wiedermann
Journal:  Middle East J Anaesthesiol       Date:  2011-10

2.  [Conversion to 2nd degree from 1st degree atrioventricular (AV) block by the reversal of neuromuscular blockade].

Authors:  H Tanaka; K Murata; A Sera; M Horibe; H Izumi; T Tsuchiya
Journal:  Masui       Date:  1991-04

3.  Neostigmine-induced bradycardia following recent vs remote cardiac transplantation in the same patient.

Authors:  S B Backman; R D Stein; F E Ralley; G S Fox
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

4.  Type I second-degree AV block after neostigmine administration in a child with renal failure.

Authors:  M D Webb
Journal:  Anesth Prog       Date:  1995

Review 5.  Heart block and prolonged Q-Tc interval following muscle relaxant reversal: a case report.

Authors:  John A Shields
Journal:  AANA J       Date:  2008-02

6.  Complete heart block following glycopyrronium/neostigmine mixture.

Authors:  M Lonsdale; J Stuart
Journal:  Anaesthesia       Date:  1989-05       Impact factor: 6.955

7.  Autonomic innervation of the human cardiac conduction system: changes from infancy to senility--an immunohistochemical and histochemical analysis.

Authors:  L T Chow; S S Chow; R H Anderson; J A Gosling
Journal:  Anat Rec       Date:  2001-10-01

8.  Carbamazepine induced atrial tachycardia with complete AV block.

Authors:  K Koutsampasopoulos; A Zotos; M Papamichalis; K Papaioannou
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

9.  Age-dependent changes in cardiac muscarinic receptor function in healthy volunteers.

Authors:  U Poller; G Nedelka; J Radke; K Pönicke; O E Brodde
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

10.  Clinical cues for detecting ictal asystole.

Authors:  Gena R Ghearing; Thomas M Munger; Allan S Jaffe; Eduardo E Benarroch; Jeffrey W Britton
Journal:  Clin Auton Res       Date:  2007-07-16       Impact factor: 4.435

View more
  1 in total

1.  Glycopyrrolate versus atropine for preventing bradycardia induced by neostigmine injection after general anesthesia surgery: a randomized open, parallel-controlled multicenter clinical trial.

Authors:  Yue Yun; Dianqing Cao; Xiaoqing Zhang; Wen Ouyang; Su Min; Jianrui Lv; Lin Li; Furong Huang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.